IRVING, Texas, July 31, 2018 — A research abstract authored by pathologists at
Inform Diagnostics has been awarded “Outstanding Abstract”
in the 2018 Therapeutic Drug Management and Toxicology Division Abstract
Competition conducted by the American Association for Clinical Chemistry (AACC).
Titled “Therapeutic Drug Monitoring of Monoclonal Antibody in Inflammatory Bowel
Disease: Laboratory Evidence to Predict Patient Responses,” the abstract describes a study of 18,837 sera samples collected
from adult and pediatric IBD patients receiving monoclonal antibody (mAb)
biologic drug treatments that were analyzed using Inform Diagnostics’
assay, which employs an ELISA-based method to measure concentrations of
both the drug and patient immunity to the drug (anti-drug antibodies).
This study provides laboratory evidence to predict patient response and
guide treatment for IBD patients. The authors are
Yun Wang, MD, PhD,
Kevin Turner, DO,
Ahmed Bedeir, MD,
Parag Patel, DO, and
James Gulizia, MD, PhD.
The Outstanding Abstract award was presented at the AACC Therapeutic Drug
Management and Toxicology Division Annual Meeting on Monday, July 30.
About Inform Diagnostics
Inform Diagnostics is the largest independent anatomic pathology lab in
the United States, chosen by clinicians every day as a vital provider
for their patients’ care. Headquartered in Irving, Texas, the organization
was founded in 1996 and previously known as Miraca Life Sciences since
2012. Inform Diagnostics’ premier medical laboratories focus on
GI pathology, dermatopathology, hematopathology, urologic pathology, and
breast pathology. Each Inform Diagnostics pathologist is a fellowship-trained
subspecialist. Learn more online about Inform Diagnostics’
extraordinary quality and service.